SMMT · Summit Therapeutics Inc.

The thesis

Summit Therapeutics' case still rests on Food and Drug Administration (FDA) approval of ivonescimab by its 14 November 2026 decision date. AstraZeneca's $2.0 billion investment, which closed on 5 October 2026, funds the company through that decision. Two dated events settle the case: full biliary tract cancer data at the European Society for Medical Oncology (ESMO) Congress on 25 October 2026, then the FDA decision.

No company news has followed the 5 October 2026 closing, and no new SEC filing has appeared since. The shares closed at $17.17 on 8 October 2026, per adjusted daily closes. That is below the $18.36 per common share AstraZeneca paid and 34.9% below the 52-week high of $26.38.

The narrative is maturing: the AstraZeneca deal has been widely covered since 28 September 2026, and no new company headline has followed the closing. The 14-day relative strength index (RSI), a momentum gauge, stood at 44.8 on 8 October 2026, which is neutral. The shares are up 12.2% over three months.

Bullish and bearish views on Summit Therapeutics Inc.

The bull case on Summit Therapeutics Inc. (SMMT), in brief: The $2.0 billion investment has closed. The bear case: The pivotal trial missed its primary survival test.

Bull case

• The $2.0 billion investment has closed. Summit and AstraZeneca each announced the closing on 5 October 2026. Before the deal, Summit's Q2 report of 23 July 2026 showed $690.7 million of cash and short-term investments, no debt, and $263.4 million of operating cash outflow in the first half of 2026.
• Two large drugmakers now run combination trials. AstraZeneca and Daiichi Sankyo announced on 2 October 2026 that they will pair ivonescimab with Datroway, starting with a Phase III trial in first-line triple-negative breast cancer. AstraZeneca's 29 September 2026 Form 6-K added gastrointestinal-cancer trials with sonesitatug vedotin.
• Biliary cancer data gets ESMO's top session. Akeso's HARMONi-GI1 trial of 682 patients in China met its overall survival endpoint against durvalumab plus chemotherapy, per topline results of 25 August 2026. Full data will be shown on 25 October 2026 in ESMO's Presidential Symposium in Madrid, per Summit's 22 September 2026 release.
• China lung-cancer survival data is significant. Summit's 13 September 2026 release reported an overall survival hazard ratio of 0.73 (95% confidence interval 0.57–0.95, p=0.009) for ivonescimab against pembrolizumab in Akeso's HARMONi-2 trial.
• Bullish targets sit well above the price. Goldman Sachs reiterated Buy with a $41 target on 29 September 2026, per Investing.com. Citi kept Buy and raised its target to $43 the same day, per Benzinga.

Bear case

• The pivotal trial missed its primary survival test. The global HARMONi trial behind the US application had an overall survival hazard ratio of 0.79 with p=0.057 at its primary analysis. Summit's 15 September 2026 update gave a Western-patient hazard ratio of 0.76, with a 95% confidence interval of 0.52–1.10 that crosses 1.0.
• The FDA named survival as the bar. Summit disclosed on 30 May 2025 that the FDA had said a statistically significant overall survival benefit would be required for approval. The HARMONi primary result does not clear that test on its own, which makes 14 November 2026 a genuine binary event.
• The first-line lung trial has already stumbled. The squamous cohort of HARMONi-3 missed at its 30 April 2026 interim analysis. Its final progression-free survival readout is due in the second half of 2026, with no date set.
• Neutral analysts see little upside. Barclays kept Equal-Weight on 1 October 2026 and raised its target only to $20, per Benzinga. HC Wainwright reiterated Neutral on 23 September 2026.
• The market priced the shares below AstraZeneca's price. The 8 October 2026 close of $17.17 sits under the $18.36 per-share equivalent of the investment. Buyers in the open market have not paid what AstraZeneca paid.

Price setup

The shares closed at $15.48 on 28 September 2026, the last close before the AstraZeneca agreement. They rose 16.34% in the 29 September 2026 pre-market session, per Benzinga, and closed at $17.31 on 6 October 2026 and $17.17 on 8 October 2026.

The $15.48 pre-deal close is the level that measures whether the partnership gain holds. A weekly close below $15.00 would erase the whole move. Above the price, the $18.36 per-share equivalent of AstraZeneca's investment and the $26.38 52-week high are the reference levels.

Crowding is visible. Benzinga reported on 1 October 2026 that Summit was among the names in Robinhood traders' largest five-day buying spree on record. That retail buying arrived ahead of a dense run of binary events: ESMO data on 25 October 2026 and the FDA decision on 14 November 2026.

Catalysts, next 30 days

• 25 October 2026 — Full HARMONi-GI1 biliary tract cancer Phase III data at the ESMO 2026 Presidential Symposium, Madrid. The size and confidence interval of the survival benefit set how much value ivonescimab earns outside lung cancer.
• ~30 October 2026, est. — Q3 2026 results and 10-Q; Summit has not announced a date. The filing shows whether the going-concern language from the Q2 filing is removed, plus Q3 cash burn and any at-the-market share sales.
• 14 November 2026 — FDA decision date for ivonescimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NSCLC) after third-generation EGFR targeted therapy. This falls just outside 30 days, and the case turns on it. Approval makes Summit a commercial company; a complete response letter (a rejection) or an extension leaves a single-asset company with no approved product.

Elapsed catalysts

• Second half of 2026, undated — HARMONi-3 squamous cohort final progression-free survival. A second miss after the 30 April 2026 interim result would weaken the Western path into first-line lung cancer. (passed 165d ago)

What would change the view

The approval case breaks if the FDA issues a complete response letter, extends its review, or calls an advisory committee before 14 November 2026. Any of those would show the agency holding Summit to the significant-survival bar it stated in 2025, which the HARMONi primary result (p=0.057) did not meet.

The broader ivonescimab case weakens if the ESMO biliary data on 25 October 2026 shows a hazard ratio with a confidence interval near 1.0, or if the HARMONi-3 squamous final analysis misses again. On price, a weekly close below $15.00, under the $15.48 pre-deal close of 28 September 2026, would show the market has given back the AstraZeneca gain. A clean Western Phase III lung-cancer win by a rival PD-1/VEGF bispecific from Pfizer/3SBio or Bristol Myers Squibb/BioNTech would also erode Summit's lead.

What it trades with

Summit trades on its own clinical and regulatory events, so trial readouts and FDA news move the shares far more than the market does. Rate pressure still matters at the margin for a cash-burning biotech: Benzinga reported on 7 October 2026 that the 30-year Treasury yield hit 5.7%, a 24-year high, as the Russell 2000 small-cap index fell.

Akeso (HK: 9926), which licensed ivonescimab to Summit and keeps China rights, is the closest read-through; Akeso trial data and China approvals move both names. AstraZeneca now holds a stake equal to about 12% of Summit's outstanding common stock, and news on AstraZeneca's antibody-drug conjugate programs, Datroway in particular, now bears on Summit. Results from rival PD-1/VEGF bispecific programs move the whole drug class together.